As Foamix Pharmaceuticals LTD (FOMX) Valuation Declined, Holder Opaleye Management Has Trimmed Its Holding; Boussard & Gavaudan Investment Management Llp Cut Its Position in Criteo S A (CRTO) by $4.89 Million as Share Price Rose

April 23, 2018 - By Michael Collier

Criteo S.A. (NASDAQ:CRTO) Logo

Boussard & Gavaudan Investment Management Llp decreased its stake in Criteo S A (CRTO) by 92.61% based on its latest 2017Q4 regulatory filing with the SEC. Boussard & Gavaudan Investment Management Llp sold 188,072 shares as the company’s stock rose 8.83% while stock markets declined. The institutional investor held 15,015 shares of the advertising company at the end of 2017Q4, valued at $397,000, down from 203,087 at the end of the previous reported quarter. Boussard & Gavaudan Investment Management Llp who had been investing in Criteo S A for a number of months, seems to be less bullish one the $1.86B market cap company. The stock increased 1.89% or $0.52 during the last trading session, reaching $28.07. About 231,338 shares traded. Criteo S.A. (NASDAQ:CRTO) has declined 47.34% since April 23, 2017 and is downtrending. It has underperformed by 58.89% the S&P500.

James A. Silverman decreased its stake in Foamix Pharmaceuticals Ltd (FOMX) by 15.94% based on its latest 2017Q4 regulatory filing with the SEC. Opaleye Management Inc sold 182,000 shares as the company’s stock declined 26.36% with the market. The hedge fund run by James A. Silverman held 960,000 shares of the specialty chemicals company at the end of 2017Q4, valued at $5.77 million, down from 1.14M at the end of the previous reported quarter. Opaleye Management Inc who had been investing in Foamix Pharmaceuticals Ltd for a number of months, seems to be less bullish one the $188.51M market cap company. The stock decreased 3.64% or $0.1899 during the last trading session, reaching $5.0201. About 47,421 shares traded. Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has declined 13.02% since April 23, 2017 and is downtrending. It has underperformed by 24.57% the S&P500.

Among 3 analysts covering Foamix Pharmaceuticals (NASDAQ:FOMX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Foamix Pharmaceuticals had 7 analyst reports since August 25, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, January 5 by H.C. Wainwright. On Wednesday, November 29 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has “Buy” rating given on Tuesday, December 5 by Guggenheim. The stock of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has “Buy” rating given on Tuesday, April 17 by H.C. Wainwright. The firm earned “Hold” rating on Tuesday, August 25 by Zacks.

Analysts await Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) to report earnings on May, 8. They expect $-0.45 earnings per share, down 15.38% or $0.06 from last year’s $-0.39 per share. After $-0.46 actual earnings per share reported by Foamix Pharmaceuticals Ltd. for the previous quarter, Wall Street now forecasts -2.17% EPS growth.

Analysts await Criteo S.A. (NASDAQ:CRTO) to report earnings on May, 2. They expect $0.26 EPS, down 7.14% or $0.02 from last year’s $0.28 per share. CRTO’s profit will be $17.19M for 26.99 P/E if the $0.26 EPS becomes a reality. After $0.91 actual EPS reported by Criteo S.A. for the previous quarter, Wall Street now forecasts -71.43% negative EPS growth.

Investors sentiment decreased to 0.76 in 2017 Q4. Its down 0.25, from 1.01 in 2017Q3. It dropped, as 53 investors sold CRTO shares while 35 reduced holdings. 25 funds opened positions while 42 raised stakes. 40.54 million shares or 18.35% less from 49.65 million shares in 2017Q3 were reported. Stratos Wealth Prns Ltd holds 100 shares or 0% of its portfolio. Alliancebernstein Lp holds 26,405 shares. Jpmorgan Chase & holds 8 shares. Tocqueville Asset Management Lp has 34,600 shares for 0.01% of their portfolio. Citadel Advsr Ltd Limited Liability Company has 0.02% invested in Criteo S.A. (NASDAQ:CRTO). Credit Suisse Ag invested in 36,909 shares or 0% of the stock. Utd Capital Advisers Ltd Llc owns 15,910 shares for 0% of their portfolio. Bnp Paribas Arbitrage Sa reported 0.01% stake. Morgan Stanley stated it has 0.01% in Criteo S.A. (NASDAQ:CRTO). Cubist Systematic Strategies Llc holds 0.14% of its portfolio in Criteo S.A. (NASDAQ:CRTO) for 103,500 shares. 621,803 were reported by Millennium Ltd Limited Liability Company. Nomura Hldgs stated it has 501,407 shares or 0.02% of all its holdings. Pictet Asset Management Limited stated it has 1.39 million shares. Gam Holding Ag has 254,581 shares for 0.2% of their portfolio. Trb Advsrs Limited Partnership invested 1.85% of its portfolio in Criteo S.A. (NASDAQ:CRTO).

Among 23 analysts covering Criteo SA (NASDAQ:CRTO), 12 have Buy rating, 0 Sell and 11 Hold. Therefore 52% are positive. Criteo SA had 62 analyst reports since July 21, 2015 according to SRatingsIntel. Cowen & Co maintained Criteo S.A. (NASDAQ:CRTO) on Tuesday, June 6 with “Buy” rating. Citigroup maintained the shares of CRTO in report on Thursday, November 2 with “Buy” rating. BMO Capital Markets downgraded the stock to “Market Perform” rating in Tuesday, January 23 report. The stock has “Buy” rating by KeyBanc Capital Markets on Wednesday, February 14. Macquarie Research upgraded the stock to “Buy” rating in Tuesday, January 2 report. The rating was maintained by BMO Capital Markets on Monday, October 30 with “Outperform”. Jefferies maintained it with “Hold” rating and $28.0 target in Thursday, December 14 report. The stock of Criteo S.A. (NASDAQ:CRTO) earned “Buy” rating by SunTrust on Thursday, December 14. The company was downgraded on Thursday, November 2 by Cowen & Co. The rating was maintained by Stifel Nicolaus on Thursday, September 14 with “Hold”.

Boussard & Gavaudan Investment Management Llp, which manages about $2.45 billion US Long portfolio, upped its stake in Constellium Nv (NYSE:CSTM) by 1.21 million shares to 2.72 million shares, valued at $30.05 million in 2017Q4, according to the filing. It also increased its holding in Ashland Global Hldgs Inc by 9,138 shares in the quarter, for a total of 113,232 shares, and has risen its stake in Tiffany & Co New (NYSE:TIF).

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Michael Collier

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts